{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T21:20:32Z","timestamp":1787779232814,"version":"build-2784847793"},"reference-count":50,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100020205","name":"Health Commission of Jiangxi Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jfma.2026.03.085","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T12:30:47Z","timestamp":1774614647000},"page":"1113-1121","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical characteristics and peripheral immune profile analysis of thymoma-associated myasthenia gravis with anti-titin antibodies: a multicenter, retrospective study"],"prefix":"10.1016","volume":"125","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-9103-5427","authenticated-orcid":false,"given":"Yeting","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusen","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyan","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziwei","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangbin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingmin","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meihong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianghong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1380-3534","authenticated-orcid":false,"given":"Daojun","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.jfma.2026.03.085_bib1","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.3389\/fimmu.2017.01785","article-title":"Immunopathogenesis in myasthenia Gravis and neuromyelitis Optica","volume":"8","author":"Wang","year":"2017","journal-title":"Front Immunol"},{"issue":"0","key":"10.1016\/j.jfma.2026.03.085_bib2","article-title":"Causal effect of vitamin D on myasthenia gravis: a two-sample Mendelian randomization study","volume":"10","author":"Fan","year":"2023","journal-title":"Front Nutr"},{"issue":"8","key":"10.1016\/j.jfma.2026.03.085_bib3","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/s00415-016-8045-z","article-title":"Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German NeurologicalSociety","volume":"263","author":"Melzer","year":"2016","journal-title":"J Neurol"},{"issue":"26","key":"10.1016\/j.jfma.2026.03.085_bib4","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1056\/NEJMra1602678","article-title":"Myasthenia gravis","volume":"375","author":"Gilhus","year":"2016","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.jfma.2026.03.085_bib5","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.1016\/j.jfma.2026.03.085_bib6","article-title":"Autoantibodies to agrin in myasthenia gravis patients","volume":"9","author":"Zhang","year":"2014","journal-title":"PLoS One"},{"issue":"0","key":"10.1016\/j.jfma.2026.03.085_bib7","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jneuroim.2016.07.001","article-title":"Autoantibody profile and clinical characteristics in a cohort of Chinese adult myasthenia gravis patients","volume":"298","author":"Hong","year":"2016","journal-title":"J Neuroimmunol"},{"issue":"0","key":"10.1016\/j.jfma.2026.03.085_bib8","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1600-0404.2006.00608.x","article-title":"Titin and ryanodine receptor antibodies in myasthenia gravis","volume":"183","author":"Skeie","year":"2006","journal-title":"Acta Neurol Scand Suppl"},{"issue":"0","key":"10.1016\/j.jfma.2026.03.085_bib9","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jneuroim.2016.01.018","article-title":"Titin antibodies in \u201cseronegative\u201d myasthenia gravis\u2014A new role for an old antigen","volume":"292","author":"Stergiou","year":"2016","journal-title":"J Neuroimmunol"},{"issue":"3","key":"10.1016\/j.jfma.2026.03.085_bib10","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1001\/archneur.62.3.442","article-title":"Striational antibodies in myasthenia gravis: reactivity and possible clinical significance","volume":"62","author":"Romi","year":"2005","journal-title":"Arch Neurol"},{"issue":"2","key":"10.1016\/j.jfma.2026.03.085_bib11","doi-asserted-by":"crossref","first-page":"449","DOI":"10.3390\/biomedicines11020449","article-title":"Immunological and structural characterization of titin main immunogenic region; I110 domain is the target of titin antibodies in Myasthenia Gravis","volume":"11","author":"Stergiou","year":"2023","journal-title":"Biomedicines"},{"issue":"0","key":"10.1016\/j.jfma.2026.03.085_bib12","article-title":"Anti-titin antibodies is associated with more frequent hospitalization to manage thymoma-associated myasthenia gravis","volume":"13","author":"Kim","year":"2022","journal-title":"Front Neurol"},{"issue":"10","key":"10.1016\/j.jfma.2026.03.085_bib13","article-title":"Inflammation and autoimmune myasthenia Gravis","volume":"14","author":"Huda","year":"2023","journal-title":"Front Immunol"},{"issue":"0","key":"10.1016\/j.jfma.2026.03.085_bib14","article-title":"High levels of serum interleukin-6 are associated with disease activity in myasthenia Gravis","volume":"358","author":"Uzawa","year":"2021","journal-title":"J Neuroimmunol"},{"issue":"9","key":"10.1016\/j.jfma.2026.03.085_bib15","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1111\/jnc.16138","article-title":"Dynamic changes of peripheral inflammatory markers link with disease severity and predict short-term poor outcome of myasthenia Gravis","volume":"168","author":"Weng","year":"2024","journal-title":"J Neurochem"},{"issue":"0","key":"10.1016\/j.jfma.2026.03.085_bib16","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jocn.2019.02.012","article-title":"Elevated expression of interleukin-33 in myasthenia Gravis patients","volume":"63","author":"Wang","year":"2019","journal-title":"J Clin Neurosci"},{"issue":"1","key":"10.1016\/j.jfma.2026.03.085_bib17","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards. Task force of the medical scientific advisory board of the myasthenia gravis foundation of America","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.jfma.2026.03.085_bib18","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1097\/JTO.0000000000000654","article-title":"The 2015 world health organization classification of tumors of the thymus: continuity and changes","volume":"10","author":"Marx","year":"2015","journal-title":"J Thorac Oncol"},{"issue":"8","key":"10.1016\/j.jfma.2026.03.085_bib19","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1007\/s00415-004-0479-z","article-title":"The significance of titin antibodies in myasthenia gravis\u2013correlation with thymoma and severity of myasthenia gravis","volume":"251","author":"Chen","year":"2004","journal-title":"J Neurol"},{"issue":"0","key":"10.1016\/j.jfma.2026.03.085_bib20","doi-asserted-by":"crossref","first-page":"S304","DOI":"10.1097\/JTO.0b013e3181f20c05","article-title":"Staging system of thymoma","volume":"5","author":"Masaoka","year":"2010","journal-title":"J Thorac Oncol"},{"issue":"11","key":"10.1016\/j.jfma.2026.03.085_bib21","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1001\/archneur.57.11.1596","article-title":"The severity of myasthenia gravis correlates with the serum concentration of titin and ryanodine receptor antibodies","volume":"57","author":"Romi","year":"2000","journal-title":"Arch Neurol"},{"issue":"6","key":"10.1016\/j.jfma.2026.03.085_bib22","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1001\/archneur.58.6.885","article-title":"Anti-titin antibodies in myasthenia gravis: tight association with thymoma and heterogeneity of nonthymoma patients","volume":"58","author":"Yamamoto","year":"2001","journal-title":"Arch Neurol"},{"issue":"3","key":"10.1016\/j.jfma.2026.03.085_bib23","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1007\/s00415-022-11485-1","article-title":"Anti-titin antibodies are associated with myocarditis in patients with myasthenia gravis","volume":"270","author":"Kim","year":"2023","journal-title":"J Neurol"},{"issue":"4","key":"10.1016\/j.jfma.2026.03.085_bib24","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/ane.12271","article-title":"Anti-titin antibodies in early- and late-onset myasthenia gravis","volume":"130","author":"Szczudlik","year":"2014","journal-title":"Acta Neurol Scand"},{"issue":"4","key":"10.1016\/j.jfma.2026.03.085_bib25","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/nri2956","article-title":"Platelets and the immune continuum","volume":"11","author":"Semple","year":"2011","journal-title":"Nat Rev Immunol"},{"issue":"8","key":"10.1016\/j.jfma.2026.03.085_bib26","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1161\/01.CIR.0000028962.04520.01","article-title":"Platelet-derived CD40L: the switch-hitting player of cardiovascular disease","volume":"106","author":"Andr\u00e9","year":"2002","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.jfma.2026.03.085_bib27","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1083\/jcb.200105058","article-title":"Activated platelets mediate inflammatory signaling by regulated interleukin 1\u03b2 synthesis","volume":"154","author":"Lindemann","year":"2001","journal-title":"J Cell Biol"},{"issue":"2","key":"10.1016\/j.jfma.2026.03.085_bib28","doi-asserted-by":"crossref","first-page":"209","DOI":"10.7150\/ijbs.15659","article-title":"Increase in peripheral blood intermediate monocytes is associated with the development of recent-onset type 1 diabetes mellitus in children","volume":"13","author":"Ren","year":"2017","journal-title":"Int J Biol Sci"},{"issue":"8","key":"10.1016\/j.jfma.2026.03.085_bib29","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s10654-021-00752-6","article-title":"Systemic inflammation markers and cancer incidence in the UK biobank","volume":"36","author":"N\u00f8st","year":"2021","journal-title":"Eur J Epidemiol"},{"issue":"3","key":"10.1016\/j.jfma.2026.03.085_bib30","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3109\/14397595.2015.1091136","article-title":"Neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) were useful markers in assessment of inflammatory response and disease activity in SLE patients","volume":"26","author":"Qin","year":"2016","journal-title":"Mod Rheumatol"},{"issue":"3","key":"10.1016\/j.jfma.2026.03.085_bib31","doi-asserted-by":"crossref","first-page":"593","DOI":"10.3390\/diagnostics12030593","article-title":"Systematic review of prognostic role of blood cell ratios in patients with gastric cancer undergoing surgery","volume":"12","author":"Schiefer","year":"2022","journal-title":"Diagnostics (Basel)"},{"issue":"6","key":"10.1016\/j.jfma.2026.03.085_bib32","first-page":"992","article-title":"Blood cell count inflammatory markers as prognostic indicators of periodontitis: a systematic review and meta-analysis","volume":"12","author":"Alm\u0103\u015fan","year":"2022","journal-title":"J PersMed"},{"issue":"1","key":"10.1016\/j.jfma.2026.03.085_bib33","article-title":"Neutrophil-lymphocyte ratio in patients with acute Schizophrenia","volume":"16","author":"Sugita","year":"2024","journal-title":"Cureus"},{"issue":"0","key":"10.1016\/j.jfma.2026.03.085_bib34","article-title":"Time course of peripheral leukocytosis and clinical outcomes after aneurysmal Subarachnoid hemorrhage","volume":"12","author":"Gusdon","year":"2021","journal-title":"Front Neurol"},{"issue":"1","key":"10.1016\/j.jfma.2026.03.085_bib35","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/acn3.51706","article-title":"The systemic inflammation markers as possible indices for predicting respiratory failure and outcome in patients with myasthenia gravis","volume":"10","author":"Huang","year":"2023","journal-title":"Ann Clin Transl Neurol"},{"issue":"0","key":"10.1016\/j.jfma.2026.03.085_bib36","article-title":"Nonlinear association of the systemic immune-inflammatory index with mortality in diabetic patients","volume":"15","author":"Meng","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"10.1016\/j.jfma.2026.03.085_bib37","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/nyas.13519","article-title":"Thymus involvement in early-onset myasthenia gravis","volume":"1412","author":"Cron","year":"2018","journal-title":"Ann N Y Acad Sci"},{"issue":"9","key":"10.1016\/j.jfma.2026.03.085_bib38","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.autrev.2013.03.010","article-title":"Etiology of myasthenia gravis: innate immunity signature in pathological thymus","volume":"12","author":"Cavalcante","year":"2013","journal-title":"Autoimmun Rev"},{"issue":"9","key":"10.1016\/j.jfma.2026.03.085_bib39","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1111\/jnc.16138","article-title":"Dynamic changes of peripheral inflammatory markers link with disease severity and predict short-term poor outcome of myasthenia Gravis","volume":"168","author":"Weng","year":"2024","journal-title":"J Neurochem"},{"issue":"1","key":"10.1016\/j.jfma.2026.03.085_bib40","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1186\/s12883-025-04271-9","article-title":"Circulating inflammatory cytokines and the risk of myasthenia gravis: a bidirectional Mendelian randomization study","volume":"25","author":"Su","year":"2025","journal-title":"BMC Neurol"},{"issue":"0","key":"10.1016\/j.jfma.2026.03.085_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40478-014-0179-6","article-title":"IL-6 and Akt are involved in muscular pathogenesis in myasthenia gravis","volume":"3","author":"Maurer","year":"2015","journal-title":"Acta Neuropathol Commun"},{"issue":"2","key":"10.1016\/j.jfma.2026.03.085_bib42","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jaut.2010.12.001","article-title":"Blocking of IL-6 suppresses experimental autoimmune myasthenia gravis","volume":"36","author":"Aricha","year":"2011","journal-title":"J Autoimmun"},{"issue":"0","key":"10.1016\/j.jfma.2026.03.085_bib43","article-title":"High levels of serum interleukin-6 are associated with disease activity in myasthenia gravis","volume":"358","author":"Uzawa","year":"2021","journal-title":"J Neuroimmunol"},{"issue":"6","key":"10.1016\/j.jfma.2026.03.085_bib44","doi-asserted-by":"crossref","DOI":"10.1111\/cns.14793","article-title":"Efficacy and safety of tocilizumab in patients with refractory generalized myasthenia gravis","volume":"30","author":"Ruan","year":"2024","journal-title":"CNS Neurosci Ther"},{"issue":"2","key":"10.1016\/j.jfma.2026.03.085_bib45","doi-asserted-by":"crossref","first-page":"824","DOI":"10.14336\/AD.2023.0528","article-title":"Responsiveness to tocilizumab in anti-acetylcholine receptor-positive generalized Myasthenia gravis","volume":"15","author":"Jia","year":"2024","journal-title":"Aging Dis"},{"issue":"4","key":"10.1016\/j.jfma.2026.03.085_bib46","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1006\/jaut.2002.0618","article-title":"Anti-TNF-alpha antibodies suppress the development of experimental autoimmune myasthenia gravis","volume":"19","author":"Duan","year":"2002","journal-title":"J Autoimmun"},{"issue":"4","key":"10.1016\/j.jfma.2026.03.085_bib47","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1600-0404.2006.00778.x","article-title":"A clinical and immunological study of a myasthenia gravis patient treated with infliximab","volume":"115","author":"Kakoulidou","year":"2007","journal-title":"Acta Neurol Scand"},{"issue":"0","key":"10.1016\/j.jfma.2026.03.085_bib48","article-title":"Exploring the therapeutic potential of \"Xiaochaihu Decoction\": a systematic review and meta-analysis on the clinical effectiveness and safety in managing cancer-related fever","volume":"15","author":"Bu","year":"2024","journal-title":"Front Pharmacol"},{"issue":"0","key":"10.1016\/j.jfma.2026.03.085_bib49","doi-asserted-by":"crossref","first-page":"333","DOI":"10.12659\/MSM.911982","article-title":"Efficacy of sublingual administration of Dermatophagoides Farinae drops for treatment of pediatric allergic rhinitis accompanied by adenoid hypertrophy and improvement of immune function","volume":"25","author":"Yu","year":"2019","journal-title":"Med Sci Monit"},{"issue":"1","key":"10.1016\/j.jfma.2026.03.085_bib50","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s40659-020-00316-0","article-title":"Daphnetin inhibits proliferation and inflammatory response in human HaCaT keratinocytes and ameliorates imiquimod-induced psoriasis-like skin lesion in mice","volume":"53","author":"Gao","year":"2020","journal-title":"Biol Res"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092966462600255X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092966462600255X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:49:28Z","timestamp":1787777368000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092966462600255X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":50,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S092966462600255X"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2026.03.085","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical characteristics and peripheral immune profile analysis of thymoma-associated myasthenia gravis with anti-titin antibodies: a multicenter, retrospective study","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2026.03.085","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2026, Formosan Medical Association. Published by Elsevier Taiwan LLC. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}